This Article Full Text Full Text (PDF) Supplemental material Other Versions of this Article: AEM.01690-07v1 74/3/653    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Hines, H. B. Articles by Schmidt, J. J. PubMed PubMed Citation Articles by Hines, H. B. Articles by Schmidt, J. J. Agricola Articles by Hines, H. B. Articles by Schmidt, J. J.

Use of a Recombinant Fluorescent Substrate with Cleavage Sites for All Botulinum Neurotoxins in High-Throughput Screening of Natural Product Extracts for Inhibitors of Serotypes A, B, and E ^,

Harry B. Hines,¹ Alexander D. Kim,^1, Robert G. Stafford,¹ Shirin S. Badie,¹ Ernst E. Brueggeman,¹ David J. Newman,² and James J. Schmidt^1*

Department of Cell Biology and Biochemistry, Integrated Toxicology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702-5011,¹ Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21701-1201²

Received 23 July 2007/ Accepted 26 November 2007

The seven serotypes of botulinum neurotoxin (BoNTs) are zinc metalloproteases that cleave and inactivate proteins critical for neurotransmission. The synaptosomal protein of 25 kDa (SNAP-25) is cleaved by BoNTs A, C, and E, while vesicle-associated membrane protein (VAMP) is the substrate for BoNTs B, D, F, and G. BoNTs not only are medically useful drugs but also are potential bioterrorist and biowarfare threat agents. Because BoNT protease activity is required for toxicity, inhibitors of that activity might be effective for antibotulinum therapy. To expedite inhibitor discovery, we constructed a hybrid gene encoding (from the N terminus to the C terminus, with respect to the expressed product) green fluorescent protein, then a SNAP-25 fragment encompassing residues Met-127 to Gly-206, and then VAMP residues Met-1 to Lys-94. Cysteine was added as the C terminus. The expressed product, which contained the protease cleavage sites for all seven botulinum serotypes, was purified and coupled covalently through the C-terminal sulfhydryl group to maleimide-activated 96-well plates. The substrate was readily cleaved by BoNTs A, B, D, E, and F. Using this assay and an automated 96-well pipettor, we screened 528 natural product extracts for inhibitors of BoNT A, B, and E protease activities. Serotype-specific inhibition was found in 30 extracts, while 5 others inhibited two serotypes.

Published ahead of print on 14 December 2007.

Supplemental material for this article may be found at http://aem.asm.org/.

Present address: U.S. Patent and Trademark Office, 400 Dulany Street, Alexandria, VA 22314.